列线图
免疫系统
生物
基因
腺癌
癌症研究
肿瘤科
内科学
免疫学
癌症
医学
遗传学
作者
Yinying Dong,Yu Xiao,Hao Song,Yi‐Ping Phoebe Chen,Bin Zheng,Xiaomeng Ji,Mingjin Xu,Jian Liu,Xiangyin Sun,Qiuxiao Wang,Ruimei Ren,Haijun Lu
出处
期刊:Cell Cycle
[Informa]
日期:2023-12-17
卷期号:22 (23-24): 2566-2583
标识
DOI:10.1080/15384101.2023.2300591
摘要
Immunogenic cell death (ICD) has been increasingly indicated to be related to caners. However, ICD's role in Lung adenocarcinoma (LUAD) is still not well investigated. Clinical data along with associated mRNA expression profiles from LUAD cases were collected in TCGA and GEO databases. 13 ICD-related genes were identified. Relations of ICD-related genes expression with prognosis of patients, tumor immune microenvironment (TIME) was analyzed. Then, candidate genes were identified and the prognostic signature were constructed. Afterwards, one nomogram incorporating those chosen clinical data together with risk scores were built. Finally, the effect of HSP90AA1, one gene of the prognostic signature, on LUAD cell were analyzed. Two clusters were identified, which were designated as the ICD-high or -low subtype according to ICD-related genes levels. ICD-high subgroup showed good prognosis, high immune cell infiltration degrees, and enhanced immune response signaling activity compared with ICD-low subtype. Moreover, we established and verified the risk signature based on ICD-related genes. High risk group predicted poor prognosis of LUAD independently and presented negative association with immune score and immune status. Furthermore, nomogram contributed to the accurate prediction of LUAD prognostic outcome. Finally, HSP90AA1 levels were remarkably elevated within tumor cells in comparison with healthy pulmonary epithelial cells. HSP90α, HSP90AA1 protein product, promoted growth, migration, and invasion of LUAD cells. Molecular subtypes and prognostic model were identified by incorporating ICD-related genes, and it was related to TIME and might be adopted for the accurate prediction of LUAD prognosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI